LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.53 USD
+0.03 (1.66%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.52 -0.01 (-0.65%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LVTX 1.53 +0.03(1.66%)
Will LVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LVTX
I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals
LVTX: HC Wainwright & Co. Lowers Price Target, Maintains Neutral Rating | LVTX Stock News
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
LAVA Therapeutics (LVTX) Downgraded by Jefferies with Lower Price Target | LVTX Stock News
LVTX Downgraded by Jefferies Following Acquisition News